xBreakthrough therapies for gastric, breast, and head and neck cancers may be approved by late 2025
Sechenov University is nearing the final stages of clinical trials for three anti-cancer drugs targeting gastric cancer, squamous cell carcinoma of the head and neck, and breast cancer. The trials are expected to conclude by the end of 2025.
The research is being conducted at the university’s Centre for Clinical Trials of Oncological Drugs, in collaboration with pharmaceutical group R-Pharm. The centre is already among the top three in Russia for patient enrolment in oncology clinical trials.
The facility has previously completed successful trials of an immunotherapy drug for metastatic melanoma, which is now in regular clinical use.
Photo: freepik.com